Username:
Password:
 

   
* * * * * * * * * * *
 
 
 
Home » News » News item details

NEW Ceftazadime/avibactam AST discs available from MAST

31 March 2017

MAST® is happy to announce the launch of a new addition to the mastdiscs® range – Ceftazadime/avibactam 10-4 (CZA14C) and Ceftazadime/avibactam 30-20 (CZA50C), which are available now!

Marketed commercially as Zavicefta, this novel compound combines ceftazidime and avibactam to provide a solution for the treatment of Gram-negative organisms that confer resistance to β-lactam antibiotics and pose a considerable threat to public health.

Ceftazidime is active against numerous clinically relevant Gram-negative bacilli including Pseudomonas aeruginosa; but is readily hydrolysed by many β-lactamases, decreasing its effect against multi -drug resistant (MDR) organisms.

Avibactam is a non-β-lactam β-lactamase inhibitor that inhibits a variety of β-lactamases including class A, class C and some class D enzymes which erode the activity of β-lactam drugs in multidrug resistant pathogens. These characteristics allow avibactam to restore the in vitro efficacy of ceftazidime by giving it a longer half-life within the body.

Ceftazadime/avibactam functions by utilising avibactam to inhibit class A and class C β-lactamases, such as extended-spectrum beta lactamases (ESBLs), Klebsiella pneumoniae producing carbapenemases (KPCs), and cephalosporinases (AmpCs), rendering them inactive. The activity of ceftazidime remains intact and active against Gram-negative bacilli, which confer resistance to β-lactam antibiotics.

 

-           Provided in cartridge format

-           Available from stock

-           Compatible with disc dispenser (MDD64)

-           Easily integrated into laboratory workflows

-          Discs for both EUCAST (CZA14C) and CLSI (CZA50C) compliance


For more information please contact sales@mastgrp.com 


« Back

 

 

Home | Contact us | Terms and Conditions

 
Our site uses cookies to enhance visitor experience.